Treatment of Inferior Vena Cava Syndrome Due to Malignant Tumor Compression or Invasion
This protocol addresses the management of inferior vena cava syndrome (IVCS) arising specifically from malignant causes — where a tumor directly compresses or invades the inferior vena cava, distinguishing it from benign aetiologies.
Clinical scenario: Malignant IVCS occurs when a tumor compresses or invades the inferior vena cava. A wide range of primary and metastatic malignancies have been associated with this presentation, including renal, adrenal, hepatocellular, pancreatic, ovarian, cervical, prostatic, and gastric carcinomas, retroperitoneal sarcomas, pheochromocytomas, metastatic pelvic or retroperitoneal nodal disease, and primary lymphomas.
Treatment approach — partial overview
For certain tumour histologies, a non-surgical systemic or radiation-based approach may serve as the primary treatment strategy. The complete, structured regimen — including the full decision algorithm and applicable interventions — is available via the link below.
References
DOI: 10.1024/0301-1526/a000919
Benign IVCS is separated from malignant IVCS.
Malignant IVCS was described in patients with renal carcinomas, adrenal carcinomas, pheochromocytomas, pancreatic carcinomas, hepatocellular carcinomas, ovarian carcinomas, cervical carcinomas, prostatic cancer, gastric cancer, retroperitoneal sarcomas, metastatic malignant disease involving the pelvic and retroperitoneal lymph nodes, and primary lymphomas.
Otherwise patients with known radio- or chemotherapy-sensitive tumors like lymphomas may be primarily treated with these modalities.
View source ↗